$9.59
0.10% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US3984384087
Symbol
GRFS

Grifols, S.A. Sponsored ADR Class B Stock price

$9.59
-0.04 0.42% 1M
+2.60 37.20% 6M
+2.15 28.90% YTD
+1.08 12.69% 1Y
+3.29 52.22% 3Y
-10.04 51.15% 5Y
-7.14 42.66% 10Y
+2.98 45.05% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.01 0.10%
ISIN
US3984384087
Symbol
GRFS
Industry

Key metrics

Basic
Market capitalization
$8.4b
Enterprise Value
$18.7b
Net debt
$10.3b
Cash
$957.2m
Shares outstanding
680.4m
Valuation (TTM | estimate)
P/E
18.8 | 10.2
P/S
1.0 | 0.9
EV/Sales
2.2 | 2.1
EV/FCF
20.1
P/B
1.4
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 1.1%
Growth 1Y | 5Y
- | -100.0%
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$8.7b | $8.9b
EBITDA
$2.7b | $2.2b
EBIT
$1.5b | $1.6b
Net Income
$346.4m | $638.0m
Free Cash Flow
$929.4m
Growth (TTM | estimate)
Revenue
9.3% | 5.5%
EBITDA
127.6% | 41.5%
EBIT
44.1% | 20.1%
Net Income
100.8% | 249.2%
Free Cash Flow
257.8%
Margin (TTM | estimate)
Gross
39.4%
EBITDA
31.0% | 24.6%
EBIT
17.8%
Net
4.0% | 7.2%
Free Cash Flow
10.7%
Financial Health
Equity Ratio
27.5%
Return on Equity
2.7%
ROCE
7.5%
ROIC
-
Debt/Equity
1.9
More
EPS
$0.5
FCF per Share
$1.4
Short interest
0.4%
Employees
24k
Rev per Employee
$350.0k
Show more

Is Grifols, S.A. Sponsored ADR Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Grifols, S.A. Sponsored ADR Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

13x Buy
68%
4x Hold
21%
2x Sell
11%

Analyst Opinions

19 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

Buy
68%
Hold
21%
Sell
11%

Financial data from Grifols, S.A. Sponsored ADR Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
8,670 8,670
9% 9%
100%
- Direct Costs 5,256 5,256
8% 8%
61%
3,414 3,414
12% 12%
39%
- Selling and Administrative Expenses 1,411 1,411
4% 4%
16%
- Research and Development Expense 460 460
15% 15%
5%
2,689 2,689
128% 128%
31%
- Depreciation and Amortization 1,146 1,146
934% 934%
13%
EBIT (Operating Income) EBIT 1,543 1,543
44% 44%
18%
Net Profit 346 346
101% 101%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Grifols, S.A. Sponsored ADR Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Grifols, S.A. Sponsored ADR Class B Stock News

Negative
Reuters
7 days ago
Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma firm Grifols to influence its share price.
Positive
Seeking Alpha
10 days ago
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Positive
Seeking Alpha
13 days ago
Grifols demonstrates strong recovery, with leverage reduced to 4.2x and dividend reinstated, supporting a renewed investment case. GRFS posted robust Q2 2025 results: 7% revenue growth, 12.5% EBITDA growth, and near-record margins, reinforcing its global plasma leadership. Valuation remains compelling, with a new price target of €23/share and a 'BUY' rating, reflecting over 100% potential upsid...
More Grifols, S.A. Sponsored ADR Class B News

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,833
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today